



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/370,373	08/10/1999	ERWIN HACKER	514413-3766	8023

20999 7590 01/27/2003

FROMMER LAWRENCE & HAUG
745 FIFTH AVENUE- 10TH FL.
NEW YORK, NY 10151

EXAMINER

CLARDY, S

ART UNIT	PAPER NUMBER
----------	--------------

1616

DATE MAILED: 01/27/2003

16

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/370,373

Applicant(s)
Hacker et al

Examiner
S. Mark Clardy

Art Unit
1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Jan 14, 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 16-38 is/are pending in the application.
- 4a) Of the above, claim(s) 19, 22, 27, 33, 34, 37, and 38 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 16-18, 20, 21, 23-26, 28-32, 35, and 36 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 6) ☐ Other:

Art Unit: 1616

Claims 16-38 are pending in this application which is now a CPA (continued prosecution application). Claims 1-15 were canceled in the preliminary amendment filed January 8, 2002, a copy of which was faxed to the USPTO on February 8, 2002, and entered after the previous office action was mailed (Paper No. 15; January 14, 2002). This office action supersedes the earlier one.

Applicants' claims are drawn to herbicidal compositions, and synergistic methods of using them, comprising components A and B:

A) a broad spectrum herbicide

- A1 glufosinate
- A2 glyphosate
- A3 imidazolinones
- A4 protoporphyrinogen oxidase (PPO) inhibitors
- A5 cyclohexanediones
- A6 heteroaryloxyphenoxypionic acids

B) a second herbicide

- B1 cyanazine, atrazine, terbuthylazine, acetochlor, metolachlor, alachlor, terbutryn, benoxacor, nicosulfuron, rimsulfuron, primisulfuron, dimethenamid, fluthiamide, sulcotrione, simazine, mesotrione, pentoxamid
- B2 pendimethalin, pyridate, iodosulfuron, metosulam, isoxaflutole, metribuzin, cloransulam, flumetsulam, linuron, florasulam isoxachlortole
- B3 bromoxynil, dicamba, 2,4-D, clopyralid, prosulfuron, thifensulfuron, carfentrazone, tritosulfuron, MCPA, halosulfuron, diflufenzopyr, sulfosulfuron.

In the preliminary amendment, applicants inserted into the independent claims a proviso statement specifically excluding several combinations which are taught in references which were cited in the European Search Report ("*" indicates they were also cited in IDS, Paper No. 7):

Art Unit: 1616

EP 569 944 (= US 5,461,019*; 5,696,031)

WO 96/41547 (=US 5,990,047*)

WO 96/32012* (=US 5,987,432).

The excluded material is:

A1 (glufosinate) + B1.5, 2.3 (metolachlor, iodosulfuron)

A2 (glyphosate) + B1.5, 2.3 (metolachlor, iodosulfuron)

A3 (imidazolinones) + B1.4, 1.5, 1.9, 1.11 (acetochlor, metolachlor, nicosulfuron, primisulfuron);

+ B2.1, 2.2 (pendimethalin, pyridate)

+ B3.1, 3.2, 3.5 (bromoxynil, dicamba, prosulfuron)

A3.3 (imazamethabenz) + B2.3 (iodosulfuron)

A5 (sethoxydim) + B1.5 (metolachlor).

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 16 and 24 (and those dependent thereon) are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The new proviso statements in claims 16 and 24 constitute new matter because there is nothing in the specification or claims as originally filed which specifically supports the exclusion of this subset of combinations. Further,

Art Unit: 1616

the material in Tables 6, 7, 10, and 19, provide data for some of these excluded species. Therefore, the specification is devoid of any teaching which distinguishes the now-excluded material from the remaining subject matter.

In Paper No. 12, applicant elected with traverse of the species comprising:

A1.2 glufosinate-ammonium¹ and

B1.16 mesotrione².

Data for the elected species is provided in Tables 4 and 11 (p. 38 and 43). Applicants traversal of the species election requirement is on the ground(s) that:

1. the invention involves synergistic herbicide combinations for controlling harmful plants in maize, and
2. “the claims are directed to synergistic herbicide combinations from distinct sets of compounds and from a common broad spectrum herbicide (A)”.

This is not found persuasive because synergy remains an unpredictable property, thus a reference against one synergistic combination is useless for any other combination of even closely analogous compounds. The instant invention comprises a variety of structurally unrelated compounds in the (B) component, and a smaller group in the (A) component. While applicants have elected glufosinate as the (A) component, it is noted that it is not the only available choice, as indicated above. Thus, the comment that all compositions have the (A) component in common is puzzling

¹Ammonium 2-amino-4-(hydroxymethylphosphinyl)butanoate

² 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione

Art Unit: 1616

since that component is itself variable. Applicants' comment that the combinations are selected from distinct sets of compounds argues in favor of a requirement to at least elect a species.

Claims 19, 22, 27, 33, 34, 37, and 38 have been held withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 14.5 (Preliminary Amendment). Note that claims 22 and 37 refer to "glyphosinate" rather than either "glufosinate" or "glyphosate". Since mesotrione is not in the B component list of claims 22 and 37, these claims would remain nonelected.

The requirement is still deemed proper and is therefore made FINAL.

Claims 16-18, 20, 21, 23-26, 28-32, 35 and 36 have been examined only insofar as they read on the elected species.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 16-18, 20, 21, 23-26, 28-32, 35 and 36 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teachings of Takematsu et al (US 4,265,654) and Carter et al (US 5,006,158).

Art Unit: 1616

Takematsu et al teach glufosinate (formula I) as a herbicidal agent which is useful also in combination with other herbicides such as the cyclohexanedione herbicide alloxydim (identified by chemical name, col 1, lines 36-38).

Carter et al teach that cyclohexanediones such as alloxydim (see generic structure at col 1, lines 40-50) and the triketones such as 2-(2-nitrobenzoyl)-1,3-cyclohexanediones (abstract) such as mesotrione (column 55, Table I-D, compound 26d) were known herbicidal agents. Also as is conventional in the art, the combination of the disclosed triketone herbicides with additional herbicidal agents is disclosed (col 93, lines 64-66).

One of ordinary skill in the art would be motivated to combine these references because it is conventional in the art to combine two or more herbicides to combine the spectrum of activity of each herbicidal agent.

Thus it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have used applicants' elected glufosinate and mesotrione together or in sequence for the control of weeds because the prior art teaches that it was well known to use glufosinate in combination with additional secondary herbicides. It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose in order to form a third composition that is to be used for the very same purpose; the idea of combining them flows logically from their having been individually taught in the prior art. In re Kerkhoven, 205 USPQ 1069.


Art Unit: 1616

The data presented in the specification do not demonstrate unexpected results because it cannot be determined if the differences between the expected and observed results are statistically significant (Tables 4 and 11, p. 38 and 43), with the possible exception of A1.2+B1.16 at 300+100 g/ha (Table 4: 95% observed vs 77% expected by Colby).

No unobvious or unexpected results are noted; no claim is allowed.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a)

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. Mark Clardy whose telephone number is (703) 308-4550.



S. Mark Clardy
Primary Examiner
AU 1616

January 21, 2003